Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193.

Autor: Tchesnokova VL; Department of Microbiology, University of Washington School of Medicine, Seattle., Rechkina E; ID Genomics, Inc, Seattle., Larson L; Department of Microbiology, University of Washington School of Medicine, Seattle., Ferrier K; Department of Microbiology, University of Washington School of Medicine, Seattle., Weaver JL; Department of Microbiology, University of Washington School of Medicine, Seattle., Schroeder DW; Department of Microbiology, University of Washington School of Medicine, Seattle., She R; Keck School of Medicine, University of Southern California, Los Angeles., Butler-Wu SM; Keck School of Medicine, University of Southern California, Los Angeles., Aguero-Rosenfeld ME; Langone Hospital, New York University., Zerr D; Seattle Children's Hospital., Fang FC; Department of Microbiology and Harborview Medical Center, University of Washington School of Medicine., Ralston J; Kaiser Permanente Washington.; Kaiser Permanente Washington Research Institute, Seattle., Riddell K; Kaiser Permanente Washington., Scholes D; Kaiser Permanente Washington.; Kaiser Permanente Washington Research Institute, Seattle., Weissman S; Seattle Children's Hospital., Parker K; ID Genomics, Inc, Seattle., Spellberg B; Keck School of Medicine, University of Southern California, Los Angeles., Johnson JR; Veterans Affairs Medical Center and University of Minnesota, Minneapolis., Sokurenko EV; Department of Microbiology, University of Washington School of Medicine, Seattle.
Jazyk: angličtina
Zdroj: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2019 Jan 07; Vol. 68 (2), pp. 334-337.
DOI: 10.1093/cid/ciy525
Abstrakt: We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.
Databáze: MEDLINE